iBio, Inc. stock is down -75% since 30 days ago. The next earnings date is Feb 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 7.69% of the previous 12 December’s closed higher than November.
iBio, Inc. provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.